Jpmorgan Chase & CO Infla Rx N.V. Transaction History
Jpmorgan Chase & CO
- $1.23 Trillion
- Q4 2024
A detailed history of Jpmorgan Chase & CO transactions in Infla Rx N.V. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 1,058 shares of IFRX stock, worth $2,010. This represents 0.0% of its overall portfolio holdings.
Number of Shares
1,058
Previous 58
1724.14%
Holding current value
$2,010
Previous $0
Infinity%
% of portfolio
0.0%
Previous 0.0%
Shares
13 transactions
Others Institutions Holding IFRX
# of Institutions
34Shares Held
13.6MCall Options Held
30.9KPut Options Held
2.1K-
Suvretta Capital Management, LLC New York, NY5.73MShares$10.9 Million0.59% of portfolio
-
683 Capital Management, LLC New York, NY2.07MShares$3.93 Million0.37% of portfolio
-
Morgan Stanley New York, NY2.04MShares$3.87 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL667KShares$1.27 Million0.0% of portfolio
-
Raymond James Financial Inc St. Petersburg, FL638KShares$1.21 Million0.0% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $84M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...